Skip Navigation
Skip to contents

대한치매학회

검색

대한치매학회 검색

일반인 공간

학회지

권호별 검색

  • HOME
  • 학회지
  • 학회지
  • 권호별 검색
LETTER TO THE EDITOR
Dementia and Neurocognitive Disorders 2023: 22: 1: 43-45

전문보기
Impact of COVID-19 Pandemic on Rate of Cognitive Impairment Screening Among the Elderly by Activity of Daily Living in Indochina: A Preliminary Report
Rujittika Mungmunpuntipantip ,1 Viroj Wiwanitkit 2,3
1 Private Academic Consultant, Bangkok, Thailand 2 Joseph Ayo Babalola University, Ikeji-Arakeji, Nigeria 3 Chandigarh University, Sahibzada Ajit Singh Nagar, Punjab, India
Impact of COVID-19 Pandemic on Rate of Cognitive Impairment Screening Among the Elderly by Activity of Daily Living in Indochina: A Preliminary Report
Rujittika Mungmunpuntipantip ,1 Viroj Wiwanitkit 2,3
1 Private Academic Consultant, Bangkok, Thailand 2 Joseph Ayo Babalola University, Ikeji-Arakeji, Nigeria 3 Chandigarh University, Sahibzada Ajit Singh Nagar, Punjab, India
Dear Editor,
The coronavirus disease 2019 (COVID-19) outbreak has impacted healthcare routine service
programs. Priority was given to COVID-19 infection prevention. Personnel and resources for the
healthcare industry were reallocated. Effect of the COVID-19 pandemic on common screening
practices in public healthcare is a fascinating subject. Prior research has amply demonstrated
the value of routine cancer screening, particularly cervical cancer screening.1
Cognitive
impairment is still a fairly common medical issue in many parts of the world, particularly
Southeast Asia. With routine screening and quick, targeted treatment, the endemicity of this
disorder is anticipated to decrease locally.2
An important factor that serves as a barometer for
the effectiveness of a public health program is the program’s coverage. In many remote places,
early diagnosis and comprehensive care continue to present significant obstacles.3
Although
effects of conventional medical care are intriguing, they are rarely discussed. According to
the study’s authors, the COVID-19 pandemic had an effect on the elderly who experienced full
cognitive impairment in areas where the disorder was a serious concern.
A preliminary study was carried out in the study province, a rural area of an Indochina
country (GPS location) (15.698448, 100.128784). It is approximately 240 kilometers from
the capital. This location is likely to be in an area where cognitive impairment is prevalent.4
Per 1,000 local elderly, there were 267 cases of congenital cognitive impairment.5
Geriatric
screening is a popular strategy that is recognized as an effective way to treat a variety of
illnesses, including genetic issues. Activities of Daily Living test is required at the first
geriatric clinical visit according to local public health policy. All geriatric patients over the
age of 60 within the primary care center's service area who could understand and attend
the screening procedure met the criteria for cognitive function screening according to local
public health standards.
If cognitive impairment was confirmed, standard specific rehabilitation care was provided.
Primary data obtained from a public source (http://203.157.71.163/hgis03/) were used for
retrospective data analysis. Each year, the rate of completion of cognitive impairment therapy
for the elderly was directly compared. Data were analyzed from before COVID-19 debuted until 2021 when COVID-19 began to affect the study environment. Data on the overall number
of senior people experiencing cognitive impairment between 2017 and 2021 are shown in
Table 1. A constant completion that was unusual in therapy was observed prior to COVID-19.
When COVID-19 and the lockout policy were adopted, therapy completion tended to decline
before increasing once the lockdown policy was lifted.
In general, governmental public data on cognitive impairment screening might be available
in a variety of settings. They are typically crude data lacking a thorough reappraisal. The
current report was not based on raw data, but on new, specific findings about the impact of
the COVID-19 outbreak. The most recent research has shown that COVID-19 has a significant
impact on how well elderly people respond to conventional cognitive impairment screening
programs. The proportion of screening coverage is considerably impacted by pandemicrelated lockdown policy, although COVID-19 might have little impact. Progress is being
made at a slower rate. The usual approach for preventing prenatal cognitive impairment was
examined in this study to see how it was impacted by the COVID-19 pandemic. To the best of
our knowledge, this is one of the earliest investigations of its kind. Knowledge gained from
this observation can be applied to the COVID-19 pandemic continuum and other potential
problems in the future.
We confirm that we have read the Journal’s position on issues involved in ethical publication
and affirm that this report is consistent with those guidelines.
Key Words:
대한치매학회지 (Dementia and Neurocognitive Disorders)

목록

더보기

Sponsor
  • 대웅제약
  • 에자이
  • 종근당
  • 명인제약
  • 유한양행
  • 룬드백
  • 제일
  • SK케미컬
  • 한독
  • 알보젠

더보기 닫기

  • 대웅제약
  • 에자이
  • 종근당
  • 명인제약
  • 유한양행
  • 룬드백
  • SK케미컬
  • 한독
  • 셀트리온
  • 로완
서울특별시 서초구 서초중앙로 18 (서초동, 서초쌍용플래티넘) 619호
  • Tel : +82-2-587-7462
  • Fax : +82-2-587-7482
  • e-mail : secretkda@thedementia.co.kr
  • 사업자등록번호 : 214-82-63838
  • 상호 : 대한치매학회
  • 대표자명 : 최성혜 이사장

Copyright © The Korean Dementia Association, All rights reserved